Business
Grapheton Inc. is Featured on The Stock Day Podcast to Discuss Advanced Neurotechnology Solutions
Grapheton Inc. is Featured on The Stock Day Podcast to Discuss Advanced Neurotechnology Solutions.
About this update from Us Nuclear Corp.
[{"type":"text","content":"LOS ANGELES, CA / ACCESSWIRE / February 11, 2021 / The Stock Day Podcast welcomed Grapheton Inc., a subsidiary of US Nuclear Corp. (OTCQB:UCLE) ("the Company") that focuses on developing cutting-edge neurotechnology solutions using brain-computer-interfaces. CEO of Grapheton, Sam Kassegne, joined Stock Day host Everett Jolly.Jolly began the interview by asking about the Company's background and current projects. Kassegne explained that Grapheton was developed at and licensed from NanoFAB.SDSU, which is part of the Center for Neurotechnology (CNT) Engineering Research Center. "The funding was to expand the realm of what we call 'brain-computer-interface'," said Kassegne. "We knew we had an interesting technology, which was getting acceptance in the research environment, and that we wanted to bring it to the market.""What is unique about Grapheton's technology compared to others who are in your space?" asked Jolly. "What is unique about Grapheton's core technology is the electrode technology," explained Kassegne. "The material that the electrode is made of is of a carbon nature," he continued, noting that the traditional materials in this space can corrode over time. "Our material is very smooth, homogenous," he said. "We have demonstrated that it will last for a very long time," shared Kassegne, adding that the technology could last up to ten years. "Imagine putting this electrode in somebody's brain and you don't have to take it out, it's going to stay for a very long period of time without corrosion. So, that's the core of our technology.""What are you looking to accomplish through this process?" asked Jolly. "We want to understand how the brain works," explained Kassegne. "A growing number of applications are coming online where such electrodes or probes are being placed in the brain and are not only recording the signals from the brain but are also stimulating the brain," he explained. "There are about 190,000 to 200,000 people around the globe where such BCI electrodes are implanted in their brains for a number of reasons, particularly treating Parkinson's disease and very chronic depressions," said Kassegne. "So, therapeutics as well as fundamental und...